GSK vs. AZN, ITH, SOPH, HCM, GRI, INDV, SLS, ERGO, SLN, and AMYT
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), HUTCHMED (HCM), Grainger (GRI), Indivior (INDV), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Silence Therapeutics (SLN), and Amryt Pharma (AMYT). These companies are all part of the "pharmaceutical products" industry.
GSK vs.
GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking.
GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.0%. AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.2%. GSK pays out 96.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 64.1% of its earnings in the form of a dividend.
GSK presently has a consensus price target of GBX 1,862.50, suggesting a potential upside of 24.29%. AstraZeneca has a consensus price target of GBX 6,303.50, suggesting a potential downside of 41.69%. Given GSK's stronger consensus rating and higher possible upside, analysts clearly believe GSK is more favorable than AstraZeneca.
GSK has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.
AstraZeneca received 774 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.78% of users gave AstraZeneca an outperform vote while only 50.37% of users gave GSK an outperform vote.
AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
45.3% of GSK shares are owned by institutional investors. Comparatively, 51.0% of AstraZeneca shares are owned by institutional investors. 1.6% of GSK shares are owned by company insiders. Comparatively, 0.0% of AstraZeneca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, GSK had 1 more articles in the media than AstraZeneca. MarketBeat recorded 3 mentions for GSK and 2 mentions for AstraZeneca. GSK's average media sentiment score of 0.22 beat AstraZeneca's score of -0.08 indicating that GSK is being referred to more favorably in the media.
Summary
GSK and AstraZeneca tied by winning 10 of the 20 factors compared between the two stocks.
Get GSK News Delivered to You Automatically
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:GSK) was last updated on 6/10/2025 by MarketBeat.com Staff
Buy GSK Stock Free GSK Stock Alerts